Paul Truex is the Chairman and CEO of Thryv Therapeutics, bringing nearly three decades of experience in life sciences. Over his career, he has played a pivotal role in more than $5 billion in life sciences financings and strategic transactions.

Before joining Thryv, Paul founded Anthera Pharmaceuticals, a publicly traded biotech company with significant clinical programs in cardiovascular disease, lupus, inflammation, and cystic fibrosis. He also served as Founder, President, and CEO of Peninsula Pharmaceuticals, an antibiotic development company acquired by Johnson & Johnson and Forest Laboratories for over $700 million.

Paul began his career in life sciences at Eli Lilly and Company, where he gained experience in business development, including the Lilly ICOS joint venture for the development of Cialis® and several successful out-licensing initiatives.

Paul currently serves on the boards of Feldan Therapeutics, Find Therapeutics, and Thryv. He is a former board member of Milestone (Nasdaq: MIST), Anthera (Nasdaq: ANTH), Trius (acquired), CymaBay (acquired), Eiger (EIGR), Protagonist (PTGX), and Peninsula Pharmaceuticals (acquired).

He obtained his Master of Business Administration from Indiana University and a Bachelor of Arts in Economics from the University of Waterloo. Paul also serves as an Acting Board Member for the Indiana University Johnson Center for Entrepreneurship and Innovation.